Celsion Buys Cancer Drug Developer

Share post:

Lenox Drive-based Celsion Corporation, an oncology drug development company, will acquire Huntsville, Alabama-based EGEN Inc., a biopharmaceutical company focused on treating cancer and difficult diseases with DNA-based immunotherapy.

Along with the company, Celsion is acquiring EGEN’s candidate immunotherapy drug EGEN-001 and its platform technologies. The drug is in early clinical trials. The platform technologies are all related to DNA and RNA. Celsion is paying $14 million in cash and shares, plus $30 million in the future if EGEN’s product hits certain development and licensing milestones.

“This transaction offers an immediately well-defined strategic fit, bringing together discovery and pre-clinical expertise with clinical and operational excellence, ground-breaking technologies with high-value clinical assets, to form a company whose synergy provides substantially more than its parts,” said Michael H. Tardugno, Celsion’s president and CEO.

Celsion Corp., 997 Lenox Drive, Suite 100, Lawrence­ville 08648; 800-262-0394; Gregory Weaver, senior VP, CFO. www.celsion.com.

CE – US1

Related articles

Trenton Walks! remembers those we have lost

Trenton Walks! announces five events that will take place in the next several weeks focusing on themes as...

Princeton Symphony Orchestra presents Sounds of the Seasons Dec. 10

The Princeton Symphony Orchestra (PSO) presents a holiday chamber concert filled with Sounds of the Season. The concert...

Lawrence delays action on proposed data center ban measure

An ordinance that would prohibit data centers anywhere in Lawrence Township has been tabled by the Township Council...

State to highlight economic benefits of cannabis businesses

The New Jersey Cannabis Regulatory Commission will highlight the economic benefits of the state’s growing cannabis industry during...